| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.87.4.1130 |
| P698 | PubMed publication ID | 8484830 |
| P2093 | author name string | Mattila K | |
| Saikku P | |||
| Leinonen M | |||
| Nieminen MS | |||
| Valtonen V | |||
| Linnanmäki E | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| Chlamydia pneumoniae | Q62869737 | ||
| P304 | page(s) | 1130-1134 | |
| P577 | publication date | 1993-04-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease | |
| P478 | volume | 87 |
| Q37879971 | A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide |
| Q37868503 | A Prospective Study of Chlamydia pneumoniae Antibodies in Children Between 7 months and 8 years of Age |
| Q37864376 | A positive association of peripheral arterial occlusive disease (PAD) and Chlamydophila (Clamydia) pneumoniae. |
| Q37871487 | Absence of Chlamydia pneumoniae in surgical specimens of coronary and carotid arteries by polymerase chain reaction |
| Q57389403 | Antibiotics for secondary prevention of coronary heart disease |
| Q24201388 | Antibiotics for secondary prevention of coronary heart disease |
| Q33935098 | Antibiotics in the prevention and treatment of coronary heart disease |
| Q37880719 | Arteriosclerosis as a sequela of chronic Chlamydia pneumoniae infection |
| Q36504586 | Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma |
| Q36422568 | Association of Chlamydia pneumoniae infection with HLA-B*35 in patients with coronary artery disease |
| Q37882083 | Atherosclerosis due to chronic arteritis caused by Chlamydia pneumoniae: a tentative hypothesis |
| Q37883441 | Atypical respiratory pathogens |
| Q33975684 | Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review |
| Q43738799 | C-Reactive protein as a risk factor for left ventricular thrombus in patients with acute myocardial infarction. |
| Q37877470 | Can an antibiotic (macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model? |
| Q37881987 | Cardiovascular disease risk from prior Chlamydia pneumoniae infection can be related to certain antigens recognized in the immunoblot profile |
| Q40905298 | Changes in the age dependence of mortality and disability: cohort and other determinants |
| Q37881299 | Characterization of a strain of Chlamydia pneumoniae isolated from a coronary atheroma by analysis of the omp1 gene and biological activity in human endothelial cells |
| Q35673398 | Chlamydia infection status, genotype, and age-related macular degeneration. |
| Q34086738 | Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old) |
| Q35367697 | Chlamydia pneumoniae (TWAR). |
| Q33732232 | Chlamydia pneumoniae and anti-infective therapy: their role in the pathogenesis and treatment of coronary artery disease |
| Q33534714 | Chlamydia pneumoniae and atherosclerosis. |
| Q77729398 | Chlamydia pneumoniae and cardiovascular disease |
| Q33659387 | Chlamydia pneumoniae and coronary heart disease |
| Q37867881 | Chlamydia pneumoniae and future risk in patients with coronary heart disease |
| Q37849596 | Chlamydia pneumoniae and helicobacter pylori serology - importance in patients with coronary heart disease |
| Q37880994 | Chlamydia pneumoniae and occlusive vascular disease: identification and characterization |
| Q37880177 | Chlamydia pneumoniae and vascular disease |
| Q35370873 | Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile |
| Q37881662 | Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up |
| Q37228857 | Chlamydia pneumoniae in atheroma: consideration of criteria for causality |
| Q33890410 | Chlamydia pneumoniae in atherosclerosis |
| Q34007947 | Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice |
| Q37873686 | Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice |
| Q35559048 | Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. |
| Q37879407 | Chlamydia pneumoniae infection is frequent but not associated with coronary arteriosclerosis in cardiac transplant recipients |
| Q37878378 | Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). |
| Q37870988 | Chlamydia pneumoniae infections prevent the programmed cell death on THP-1 cell line |
| Q33763030 | Chlamydia pneumoniae, asthma, and COPD: what is the evidence? |
| Q37875263 | Chlamydia pneumoniae, the Heart, and Coronary Artery Disease: Is There a Cause and Effect Relationship? |
| Q37858226 | Chlamydia pneumoniae-specific serum immune complexes in patients with multiple sclerosis. |
| Q33821294 | Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis |
| Q33935055 | Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions |
| Q79299394 | Chronic infection and coronary artery disease |
| Q33843633 | Chronic infection and coronary artery disease |
| Q37862624 | Chronic peripheral arteriopathy is associated with seropositivity to Chlamydia pneumoniae |
| Q73351167 | Circulating immune complexes and complement C4 null alleles in patients in patients operated on for premature atherosclerotic peripheral vascular disease |
| Q43590989 | Circulating immune complexes induced by food proteins implicated in precocious myocardial infarction |
| Q33971224 | Circulating nucleic acids of Chlamydia pneumoniae and cytomegalovirus in patients undergoing coronary angiography |
| Q37885334 | Clinical features of Chlamydia pneumoniae acute respiratory infection |
| Q40109843 | Current treatment and future prospects for the management of acute coronary syndromes: consensus recommendations of the 1997 ushuaia conference, tierra del fuego, Argentina |
| Q37877605 | De Novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. |
| Q37883353 | Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms |
| Q37883146 | Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves |
| Q33781183 | Diagnosis and management of patients with unstable angina |
| Q40968088 | Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells |
| Q35110637 | Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis |
| Q37870396 | Enterovirus, mycoplasma and other infections as predictors for myocardial infarction |
| Q33935008 | Epidemiologic association of Chlamydia pneumoniae and atherosclerosis: the initial serologic observation and more |
| Q33762140 | Epidemiology of Chlamydia pneumoniae in atherosclerosis |
| Q37887313 | Experimental Chlamydia pneumoniae infection in mice: effect of reinfection and passive immunization |
| Q35774105 | Experimental rabbit models of Chlamydia pneumoniae infection |
| Q30884143 | Genetic differences in the Chlamydia trachomatis tryptophan synthase alpha-subunit can explain variations in serovar pathogenesis |
| Q37870852 | High oxidized LDL and elevated plasma homocysteine contribute to the early reduction of myocardial flow reserve in healthy adults. |
| Q36503604 | High prevalence of antibodies to Chlamydia pneumoniae; determinants of IgG and IgA seropositivity among Jerusalem residents |
| Q33286200 | Higher incidence of persistent chronic infection of Chlamydia pneumoniae among coronary artery disease patients in India is a cause of concern |
| Q37872162 | Hyperhomocyst(e)inemia and Chlamydia pneumoniae IgG seropositivity in patients with coronary artery disease |
| Q37879806 | IgG subclass-specific antibodies in Chlamydia pneumoniae infections |
| Q37862860 | Immunoglobulin A and CD8 T-cell mucosal immune defenses protect against intranasal infection with Chlamydia pneumoniae. |
| Q37878292 | Immunoglobulin A antibodies against Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysm. |
| Q41779449 | Immunology of non-trachomatis chlamydial infection |
| Q36524413 | In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae |
| Q50962820 | Indications of an autoimmune component in LP(a) associated disorders. |
| Q37879018 | Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes |
| Q35425745 | Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha. |
| Q37861388 | Interaction between Chlamydia pneumoniae seropositivity, inflammation and risk factors for atherosclerosis in patients with severe coronary stenosis. |
| Q34237370 | Is the observed association between periodontitis and atherosclerosis causal? |
| Q37868911 | Joint effects of Chlamydia pneumoniae infection and classic coronary risk factors on risk of acute myocardial infarction |
| Q37397602 | Laboratory diagnosis of persistent human chlamydial infection. |
| Q37878909 | Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease |
| Q37878373 | Lymphotoxin inhibits Chlamydia pneumoniae growth in HEp-2 cells. |
| Q37856198 | Microbial risk factors of cardiovascular and cerebrovascular diseases: potential therapeutical options |
| Q37872190 | No causal association between inflammation and Chlamydia pneumoniae in patients with chronic ischemic arterial disease |
| Q37867718 | Oxidized LDL further enhances expression of adhesion molecules in Chlamydophila pneumoniae-infected endothelial cells |
| Q37879499 | Pathogenesis of atherosclerosis: a possible relation to infection |
| Q36181163 | Persistent infection and vascular disease: a systematic review |
| Q37869378 | Prevalence of Chlamydia pneumoniae in the atherosclerotic plaque of patients with unstable angina and its relation with serology |
| Q37880214 | Prevalence of Chlamydia pneumoniae specific antibodies in different clinical situations and healthy subjects in Izmir, Turkey |
| Q40569596 | Protein composition of circulating immune complexes in patients with periodic disease complicated or not complicated by renal amyloidosis |
| Q37883934 | Rabbit model for Chlamydia pneumoniae infection |
| Q37882250 | Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group |
| Q37866100 | Relationship between the peripheral arterial occlusive disease and the infection by Chlamydophila pneumoniae |
| Q34698619 | Review of evidence for a connection between Chlamydia pneumoniae and atherosclerotic disease |
| Q37879495 | Seroepidemiological evidence for an association between Chlamydia pneumoniae and atherosclerosis |
| Q37859518 | Serological Evidence of Chronic Chlamydia pneumoniae Infection in Coronary Artery Disease |
| Q37883417 | Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer |
| Q37879931 | Serological evidence of an association between chlamydial infections and malignant lymphomas |
| Q37132394 | Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. |
| Q37884209 | Serological response to Chlamydia pneumoniae in patients with sarcoidosis |
| Q35764383 | Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis |
| Q34075142 | The association of infection and coronary artery disease: an update |
| Q37867657 | The mechanisms by which infectious agents may contribute to atherosclerosis and its clinical manifestations |
| Q33770472 | The possible role of infections in acute myocardial infarction |
| Q43427761 | The role of Chlamydia in coronary heart disease-fact or fiction? |
| Q37880009 | The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection |
| Q37873906 | Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial |
Search more.